From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?

Wang, L., Liu, F., Li, J., Ma, L., Feng, H., Liu, Q., Cho, W. C., Chen, H., Chen, H., Guo, H., Li, Z., Howard, S. C., Li, M., Shan, B., Gu, W., & Ji, J. (2021). From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific? Journal of Personalized Medicine, 11(9), 914. https://doi.org/10.3390/jpm11090914
Authors:
Lishi Wang
Fengxia Liu
Jing Li
Li Ma
Helin Feng
Qingyi Liu
William C Cho
Haiyong Chen
Hong Chen
Hua Guo
Zhujun Li
Scott C Howard
Minghui Li
Baoen Shan
Weikuan Gu
Jiafu Ji
Affiliated Authors:
Hua Guo
Columbia Affiliation:
Author Keywords:
cancer
clinical predictor
drug
hazard ratio
lung
smoking
elink
Publication Type:
Article
Unique ID:
10.3390/jpm11090914
PMID:
34575691
DOI:
10.3390/jpm11090914
Journal:
Journal of Personalized Medicine
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: